CSL Limited Annual Report 2022/23 67 Bill Mezzanotte MD, MPH Age 64 Executive Vice President, Head Research & Development and Chief Medical Officer As the Head of Research & Development (R&D) and Chief Medical Officer, Bill is responsible for developing and executing CSL’s R&D strategy and portfolio, creating the pipeline and R&D capabilities that will help the CSL Behring, CSL Seqirus and CSL Vifor businesses grow in the decades ahead. These R&D capabilities include identifying and developing all scientific platforms, skills and expertise necessary for success in rare and serious diseases and vaccines. Bill, who has been leading R&D since October 2018, initially joined CSL as Head of Clinical Development in 2017. Prior to CSL, Bill was senior vice president and therapeutic area head for the respiratory unit for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Bill obtained his MD at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine. Since 2020, Bill has served as a member of the Board of Directors of the Philadelphia-based University City Science Center and in 2021-2023 he served on the Board of Directors for BELLUS Health. Andy Schmeltz BA (Economics) MBA (Marketing & Finance) Age 52 Executive Vice President, CSL Behring Business Unit Andy was appointed Executive Vice President, CSL Behring in July 2023. He is responsible for commercial development and operations, therapeutic area strategy, market access, CSL Plasma strategy and operations, supply chain, operations, manufacturing, procurement, planning, and quality across the CSL Behring business unit. Prior to joining CSL, Andy was with Pfizer for 20 years, most recently as Head of enterprise-wide Commercial Strategy & Innovation, leading investment decisions. For five years, he was global president and general manager of Pfizer Oncology, where he managed a $12 billion portfolio of 24 medicines with 2,800 employees. Andy also spearheaded several acquisitions and integrations during his time at Pfizer. Andy is an established cross-functional healthcare leader who has held various roles across multiple disciplines during his 25-plus years in the industry. Elizabeth Walker BA, MS (Organisational Development and Leadership) Age 53 Executive Vice President, Chief Human Resources Officer Elizabeth Walker leads Global Human Resources for the CSL Group of Companies and its people and culture strategy, supporting a diverse population of more than 32,000 employees around the world. Elizabeth joined CSL in 2016 and was appointed Chief Human Resources Officer in December 2017. Previously, she held a variety of HR leadership positions at Campbell Soup Company, most recently as Vice President of Global Talent Management. With a career spanning more than 30 years, she has extensive human resources and management consulting expertise and a distinguished record of results in growth businesses and M&A environments and within a diverse set of industries, including healthcare, financial services and consumer products. Elizabeth holds a Master of Science degree in organisation development and leadership from St. Joseph’s University and a Bachelor of Arts degree from Carnegie Mellon University.
RkJQdWJsaXNoZXIy MjE2NDg3